Data Science Conference

The emergence of artificial intelligence, machine learning, and other analytical approaches alongside new sources of vast quantities of health-related data and technical capabilities for storage and computation have incited a call for innovation in drug and device development and commercialization. The impact is potentially wide ranging. Beginning with streamlining the operation of clinical trials such as data driven site selection or algorithmic identification of potential data errors, including new clinical trial designs such as using synthetic controls, decentralized trials, or novel endpoints, and then extending to our clinical and scientific understanding of diseases. Many of these innovations utilize data sources other than the gold standard randomized controlled trial, like omics data, real-world data, or even social media. In this session, we will hear from visionaries in data science, learn about data sources and data sharing programs, and discuss the opportunities and challenges as our industry adapts to incorporate these ideas.